Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Mar;19(115):7-23.
doi: 10.1183/09059180.00008009.

Treatment of COPD: from pharmacological to instrumental therapies

M Alifano  1 , A Cuvelier, A Delage, N Roche, B Lamia, L C Molano, L-J Couderc, C-H Marquette, P Devillier
Affiliations
Review

Treatment of COPD: from pharmacological to instrumental therapies

M Alifano et al. Eur Respir Rev. 2010 Mar.
No abstract available

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
The Zephyr valve system (Emphasys Medical, Redwood City, CA, USA). A: bird’s beak unilateral valve; B: metallic nitinol structure; C: polyurethane membrane.
FIGURE 2.
FIGURE 2.
The Zephyr valve in vivo. The valve was implanted at the orifice of a sub-segmental bronchus. The images show a closed valve on inspiration (a) which opens on expiration (b).
FIGURE 3.
FIGURE 3.
Left upper lobe complete atelectasis 2 days after implantation of four endobronchial valves into the left upper lobe in a patient with emphysema. a) Chest radiograph after implantation of the valve. Computed tomography scan b) before and c) after implantation. The left upper lobe is circled in red and the lower lobe in blue.
See this image and copyright information in PMC

References

    1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532–555. - PubMed
    1. Herland K, Akselsen JP, Skjonsberg OH, et al. How representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease? Respir Med 2005; 99: 11–19. - PubMed
    1. Beasley R, Weatherall M, Travers J, et al. Time to define the disorders of the syndrome of COPD. Lancet 2009; 374: 670–672. - PubMed
    1. Puhan MA, Schüneman HJ. How to increase the value of randomised trials in COPD research. Eur Respir J 2009; 34: 552–558. - PubMed
    1. Halpin DMG, Tashkin DP. Defining disease modification in chronic obstructive Pulmonary disease. COPD 2009; 6: 211–225. - PMC - PubMed

MeSH terms

Substances